Clinical Trial Update: A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019) [Phase 3]

View source ↗

Summary

Phase 3 study of Omarigliptin (MK-3102) in people with type 2 diabetes and chronic kidney disease or dialysis; trial completed and results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Kidney Failure On Dialysis
• Type 2 Diabetes Mellitus

Drugs mentioned

• Omarigliptin (omarigliptin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2017-02-23